Dengvaxia Controversy
Also known as: Dengvaxia scandal · Dengvaxia issue · Philippine dengue vaccine controversy
Definition
The Dengvaxia controversy erupted in the Philippines in late 2017 when the manufacturer Sanofi Pasteur announced that its dengue vaccine Dengvaxia could increase the risk of severe dengue in people who had never been infected with the virus before vaccination. Because around 830,000 Filipino schoolchildren had already been vaccinated under a government program begun in 2016, the disclosure triggered suspension of the campaign, congressional inquiries, criminal charges, and a collapse in public confidence in vaccines.
Identities (Wikipedia/Wikidata/DBpedia)
- Wikipedia: https://en.wikipedia.org/wiki/Dengvaxia_controversy
- Wikidata: https://www.wikidata.org/wiki/Q48802585
- DBpedia: https://dbpedia.org/page/Dengvaxia_controversy
Also Known As
- Dengvaxia scandal
- Dengvaxia issue
- Philippine dengue vaccine controversy
Examples and Analogies
Dengvaxia became a cautionary tale in vaccinology: a medicine beneficial to those previously exposed to dengue carried a paradoxical risk for the seronegative, so the failure was less about the product alone than about rolling out a first-of-its-kind vaccine at population scale before risk stratification was possible.
Usage Scenarios
The controversy is invoked in public-health teaching on risk communication and pharmacovigilance, in legal proceedings against officials and executives, in legislative reviews of procurement, and in research on vaccine hesitancy, which linked the episode to drops in immunization coverage in subsequent years.
Strategies
Lessons drawn include pre-vaccination screening when a product’s benefit depends on prior exposure, staged rather than nationwide rollouts of novel vaccines, transparent publication of interim trial analyses, and proactive communication that distinguishes alleged from established harm during crises.
Security and Safety Measures
Reforms emphasized stronger adverse-event monitoring and reporting, informed-consent processes for new vaccines, cold-chain and records management so recipients can be followed up, and protection of health workers who faced threats while immunization programs collapsed.
Historical Context
Dengvaxia was licensed in the Philippines at the end of 2015 and the school-based vaccination drive launched in 2016 as the world’s first public dengue immunization program. On November 29, 2017, Sanofi’s advisory on severity risk for seronegative recipients led the Department of Health to suspend the program; investigations and suits followed, involving officials of the previous and sitting administrations.
Challenges and Controversies
Scientific reviews found no confirmation that Dengvaxia caused the deaths later attributed to it in public discourse, while families and some officials pressed the opposite view, and this gap between allegation and evidence fueled prolonged litigation, political conflict, and a measles resurgence associated with falling vaccine confidence.
Related Topic
Department of Health